Not provided
Not provided
Not provided
Not provided
Not provided
On 25April2014, study was terminated before any dosing due to an AE of safety concern that occurred in protocol B1731003 with the same drug.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A Phase 2a study to evaluate the effects of an investigational compound administered at 200 mg, twice daily (BID), for 6 weeks, with canagliflozin, in adult subjects with Type 2 Diabetes Mellitus (T2DM).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| PF-05175157 | Experimental |
| |
| Placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PF-05175157 | Drug | Tablet, 200 mg, twice daily, 6 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo | Week 0, 4 |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in Weighted Mean Daily Glucose (WMDG) when compared to placebo | Weeks 0 and 4 | |
| Change from baseline in fasting plasma glucose | Weeks 0, 2, 4 and 6 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Pfizer Investigational Site | DeLand | Florida | 32720 | United States |
Not provided
| Label | URL |
|---|---|
| To obtain contact information for a study center near you, click here. | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo |
| Drug |
Tablet, 0 mg, twice daily, 2 weeks |
|
| Change from baseline in Glycosylated Hemoglobin (HbA1c) |
| Weeks 0, 4 and 6 |
| Change from baseline in fasting total cholesterol | Weeks 0, 4 and 6 |
| Change from baseline in glucose AUC(0-5) during mixed meal tolerance test (MMTT) | Weeks 0, 4 and 6 |
| Change from baseline in insulin AUC(0-5) during mixed meal tolerance test (MMTT) | Weeks 0, 4 and 6 |
| Change from baseline in C-peptide AUC(0-5) during mixed meal tolerance test (MMTT) | Weeks 0, 4 and 6 |
| Change from baseline in ratio of AUC(0-5) insulin to AUC(0-5) glucose during the MMTT | Weeks 0, 4 and 6 |
| Change from baseline in ratio of AUC (0-5) C-peptide to AUC(0-5) glucose during the MMTT | Weeks 0, 4 and 6 |
| Change from baseline in homeostatic model assessment for insulin resistance (HOMA IR) | Weeks 0, 4 and 6 |
| Change from baseline in homeostatic model assessment for β-cell function (HOMA B) | Weeks 0, 4 and 6 |
| Change from baseline in low density lipoprotein cholesterol (LDL-C) | Weeks 0, 4 and 6 |
| Plasma concentrations for PF-05175157 | Weeks 2, 4 and 6 |
| Percent change from baseline in body weight | Weeks 0, 4 and 6 |
| Change from baseline in high density lipoprotein cholesterol (HDL-C) | Weeks 0, 4 and 6 |
| Change from baseline in triglycerides | Weeks 0, 4 and 6 |
| Change from baseline in non-HDL cholesterol | Weeks 0, 4 and 6 |
| Change from baseline in very low density lipoprotein (VLDL) | Weeks 0, 4 and 6 |
| ID | Term |
|---|---|
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided